This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these therapies, especially in patients with ischemic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $443,544 to Dasisimulations LLC to develop and validate an AI-driven software platform for automating critical measurements required for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The software leverages convolutional neural networks to automatically extract necessary anatomical measurements from CT imaging data, reducing the...
This Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, was awarded under the Cardiovascular Diseases Research program (CFDA 93.837) to develop clinical software to support quantitative analysis and interpretation of myocardial contrast echocardiography (MCE) data. Narnar, LLC received $757,197 to create software modules that enhance MCE's ability to identify coronary microvascular dysfunction (MVD). The software will average...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $656,751 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Third Coast Dynamics, Inc. The grant will fund the development and validation of an AI-based platform called TCDFLOW that can provide 4D hemodynamic output directly from routine clinical anatomic images, replacing the need for the specialized 4D flow MRI technique. This will address limitations...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $437,461 to 3DT Holdings, LLC, a minority-owned biomedical engineering company, to develop a novel stabilization catheter for His pacing lead implant. The goal is to refine the design of a deployable suction flute-tipped lead placement sheath to improve the mapping and placement of His leads, which are used in cardiac resynchronization...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $834,249 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Cedars-Sinai Medical Center. The award, running from August 1, 2024 to July 31, 2025, will support a comprehensive study comparing long-term clinical outcomes, safety, and patient-reported measures between transcatheter and surgical treatment of degenerative mitral regurgitation, a common heart valve...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $294,023 to Heartlung Corporation to develop and validate an FDA-designated breakthrough AI tool called AUTOCHAMBER. The AUTOCHAMBER AI is designed to opportunistically screen existing chest CT scans to detect enlarged cardiac chambers and thickened left ventricular walls, which can indicate increased risk of atrial fibrillation,...
This Project Grant award of $810,650 from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Cedars-Sinai Medical Center to develop and validate an AI-enabled algorithm for characterizing fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and patient outcomes following valve replacement surgery. The project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $753,813 to Yale University to conduct research on using machine learning and artificial intelligence techniques to predict cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key objectives of the project are to: 1) use convolutional neural networks on cardiac MRI data to...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 project grant to Case Western Reserve University. The 4-year grant, effective September 1, 2024, supports the development and validation of a novel "transfer volume regression" model to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is funding the development and validation of a machine learning-based software tool for optimizing the placement of the MitraClip device to treat mitral regurgitation. The $2,027,737 award to 3DT Holdings, LLC, a minority-owned biomedical engineering company, will support the creation of a dataset of patient data to model mitral valve geometry, mitral regurgitation, mean left atrial pressure, and stresses on the mitral valve leaflets and left ventricle. This dataset will then be used to train a machine learning model that can predict these parameters from echocardiography images, with the goal of automating the process of determining optimal MitraClip placement. The project aims to validate the software tool's performance through animal studies and prepare a submission package for the FDA as a software-as-a-medical-device. The award period runs from September 2024 through March 2027.